CN102573470A - 用于介入治疗和根除癌症的ite - Google Patents

用于介入治疗和根除癌症的ite Download PDF

Info

Publication number
CN102573470A
CN102573470A CN2010800474493A CN201080047449A CN102573470A CN 102573470 A CN102573470 A CN 102573470A CN 2010800474493 A CN2010800474493 A CN 2010800474493A CN 201080047449 A CN201080047449 A CN 201080047449A CN 102573470 A CN102573470 A CN 102573470A
Authority
CN
China
Prior art keywords
ite
cancer
structural formula
analogue
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2010800474493A
Other languages
English (en)
Chinese (zh)
Inventor
宋嘉盛
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to CN201611027233.6A priority Critical patent/CN106588908A/zh
Publication of CN102573470A publication Critical patent/CN102573470A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • E—FIXED CONSTRUCTIONS
    • E04—BUILDING
    • E04D—ROOF COVERINGS; SKY-LIGHTS; GUTTERS; ROOF-WORKING TOOLS
    • E04D1/00—Roof covering by making use of tiles, slates, shingles, or other small roofing elements
    • E04D1/30—Special roof-covering elements, e.g. ridge tiles, gutter tiles, gable tiles, ventilation tiles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L75/00—Compositions of polyureas or polyurethanes; Compositions of derivatives of such polymers
    • C08L75/04—Polyurethanes
    • E—FIXED CONSTRUCTIONS
    • E04—BUILDING
    • E04D—ROOF COVERINGS; SKY-LIGHTS; GUTTERS; ROOF-WORKING TOOLS
    • E04D1/00—Roof covering by making use of tiles, slates, shingles, or other small roofing elements
    • E04D1/12—Roofing elements shaped as plain tiles or shingles, i.e. with flat outer surface
    • E04D1/20—Roofing elements shaped as plain tiles or shingles, i.e. with flat outer surface of plastics; of asphalt; of fibrous materials
    • E—FIXED CONSTRUCTIONS
    • E04—BUILDING
    • E04D—ROOF COVERINGS; SKY-LIGHTS; GUTTERS; ROOF-WORKING TOOLS
    • E04D1/00—Roof covering by making use of tiles, slates, shingles, or other small roofing elements
    • E04D1/28—Roofing elements comprising two or more layers, e.g. for insulation
    • H—ELECTRICITY
    • H02—GENERATION; CONVERSION OR DISTRIBUTION OF ELECTRIC POWER
    • H02S—GENERATION OF ELECTRIC POWER BY CONVERSION OF INFRARED RADIATION, VISIBLE LIGHT OR ULTRAVIOLET LIGHT, e.g. USING PHOTOVOLTAIC [PV] MODULES
    • H02S20/00—Supporting structures for PV modules
    • H02S20/20—Supporting structures directly fixed to an immovable object
    • H02S20/22—Supporting structures directly fixed to an immovable object specially adapted for buildings
    • H02S20/23—Supporting structures directly fixed to an immovable object specially adapted for buildings specially adapted for roof structures
    • H02S20/25—Roof tile elements
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G2101/00—Manufacture of cellular products
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02B—CLIMATE CHANGE MITIGATION TECHNOLOGIES RELATED TO BUILDINGS, e.g. HOUSING, HOUSE APPLIANCES OR RELATED END-USER APPLICATIONS
    • Y02B10/00—Integration of renewable energy sources in buildings
    • Y02B10/10—Photovoltaic [PV]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02E—REDUCTION OF GREENHOUSE GAS [GHG] EMISSIONS, RELATED TO ENERGY GENERATION, TRANSMISSION OR DISTRIBUTION
    • Y02E10/00—Energy generation through renewable energy sources
    • Y02E10/50—Photovoltaic [PV] energy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Architecture (AREA)
  • Structural Engineering (AREA)
  • Civil Engineering (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Polymers & Plastics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
CN2010800474493A 2009-11-02 2010-10-14 用于介入治疗和根除癌症的ite Pending CN102573470A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201611027233.6A CN106588908A (zh) 2009-11-02 2010-10-14 用于介入治疗和根除癌症的ite

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US25742209P 2009-11-02 2009-11-02
US61/257,422 2009-11-02
PCT/US2010/052729 WO2011053466A1 (en) 2009-11-02 2010-10-14 Ite for cancer intervention and eradication

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201611027233.6A Division CN106588908A (zh) 2009-11-02 2010-10-14 用于介入治疗和根除癌症的ite

Publications (1)

Publication Number Publication Date
CN102573470A true CN102573470A (zh) 2012-07-11

Family

ID=43922453

Family Applications (2)

Application Number Title Priority Date Filing Date
CN2010800474493A Pending CN102573470A (zh) 2009-11-02 2010-10-14 用于介入治疗和根除癌症的ite
CN201611027233.6A Pending CN106588908A (zh) 2009-11-02 2010-10-14 用于介入治疗和根除癌症的ite

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201611027233.6A Pending CN106588908A (zh) 2009-11-02 2010-10-14 用于介入治疗和根除癌症的ite

Country Status (9)

Country Link
US (6) US8604067B2 (https=)
EP (2) EP3689347A1 (https=)
JP (1) JP5598775B2 (https=)
CN (2) CN102573470A (https=)
AU (1) AU2010313622B2 (https=)
CA (1) CA2776319C (https=)
ES (1) ES2791684T3 (https=)
NZ (2) NZ599896A (https=)
WO (1) WO2011053466A1 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108239083A (zh) * 2016-12-26 2018-07-03 上海正基医药科技有限公司 芳香烃受体调节剂
CN113906021A (zh) * 2019-04-15 2022-01-07 阿里根公司 手性吲哚化合物及其用途

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011503232A (ja) 2007-11-20 2011-01-27 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッド 免疫応答の調節
AU2010313622B2 (en) 2009-11-02 2014-08-14 Ahr Pharmaceuticals, Inc. ITE for cancer intervention and eradication
US10632106B2 (en) 2009-11-02 2020-04-28 Ariagen, Inc. Methods of cancer treatment with 2-(1′H-Indole-3′-carbonyl)-thiazole-4-carboxylic acid methyl ester
AR079814A1 (es) 2009-12-31 2012-02-22 Otsuka Pharma Co Ltd Compuestos heterociclicos, composiciones farmaceuticas que los contienen y sus usos
AU2015315132B2 (en) 2014-09-12 2020-04-09 Ariagen, Inc. Efficient and scalable systhesis of 2-(1'H-indole-3'-carbonyl)-thiazole-4-carboxylic acid methyl ester and its structural analogs
US20180071376A1 (en) 2015-03-23 2018-03-15 The Brigham And Women`S Hospital, Inc. Tolerogenic nanoparticles for treating diabetes mellitus
TWI674260B (zh) * 2017-02-01 2019-10-11 德商菲尼克斯製藥股份有限公司 芳基烴受體(AhR)調節劑化合物
TWI752155B (zh) * 2017-02-01 2022-01-11 德商菲尼克斯製藥股份有限公司 芳香烴受體(AhR)調節劑化合物
EP3713937A2 (en) 2017-11-20 2020-09-30 Ariagen, Inc. Indole compounds as aryl hydrocarbon receptor (ahr) modulators
US11136318B2 (en) 2019-06-21 2021-10-05 Noramco, Llc Processes for the preparation of aryl hydrocarbon receptor ligands
US20210300912A1 (en) 2019-12-20 2021-09-30 Ikena Oncology, Inc. Aryl hydrocarbon receptor (ahr) agonists and uses thereof
CA3162388A1 (en) 2019-12-20 2021-06-24 Alfredo C. Castro 4-phenyl-n-(phenyl)thiazol-2-amine derivatives and related compounds as aryl hydrocarbon receptor (ahr) agonists for the treatment of e.g. angiogenesis implicated or inflammatory disorder
CN111067895A (zh) * 2020-01-14 2020-04-28 广东医科大学 Ite在制备预防和/或治疗心肺循环系统疾病的药物中的应用
WO2022133480A1 (en) 2020-12-18 2022-06-23 Ikena Oncology, Inc. Aryl hydrocarbon receptor (ahr) agonists and uses thereof
WO2022246907A1 (zh) * 2021-05-27 2022-12-01 山东大学 一类含有2,4-噻唑环的化合物及其制备方法和应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020183524A1 (en) * 2001-02-14 2002-12-05 Deluca Hector F. Preparations and use of an Ah receptor ligand, 2-(1'h-indole-3'-carbonyl)-thiazole-4-carboxylic acid methyl ester
EP1842541A1 (en) * 2006-03-29 2007-10-10 G.I.M.-Gesellschaft Für Innovative Medizin Gmbh Nfg Ohg Plant components and extracts and uses thereof
WO2009067349A2 (en) * 2007-11-20 2009-05-28 The Brigham And Women's Hospital, Inc. Modulation of the immune response
WO2009070645A1 (en) * 2007-11-29 2009-06-04 The Ohio University Research Foundation Indoles, derivatives, and analogs thereof and uses thereof
WO2009117597A1 (en) * 2008-03-21 2009-09-24 The Brigham And Women's Hospital, Inc. Modulation of the immune response

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5811425A (en) 1997-03-04 1998-09-22 Abbott Laboratories Heterocyclic compounds as COX-2 inhibitors
US7709520B2 (en) 2000-10-06 2010-05-04 The Texas A&M University System Diindolylmethane and C-substituted diindolylmethane compositions and methods for the treatment of multiple cancers
US7419992B2 (en) 2001-02-14 2008-09-02 Wisconsin Alumni Research Foundation Use of aryl hydrocarbon receptor ligand as a therapeutic intervention in angiogenesis-implicated disorders
US20020177594A1 (en) 2001-03-14 2002-11-28 Curtin Michael L. Inhibitors of histone deacetylase
JP4445266B2 (ja) 2002-02-12 2010-04-07 ウイスコンシン アラムナイ リサーチ フオンデーシヨン Ａｈ受容体のリガンドとしてのインドールチアゾール化合物の合成
KR100674769B1 (ko) 2003-01-02 2007-02-28 에프. 호프만-라 로슈 아게 신규 씨비 1 수용체 역작용제
TW200621766A (en) 2004-09-17 2006-07-01 Hoffmann La Roche Substituted hydantoins
AU2010313622B2 (en) 2009-11-02 2014-08-14 Ahr Pharmaceuticals, Inc. ITE for cancer intervention and eradication
US20130338201A1 (en) 2009-11-02 2013-12-19 Ahr Pharmaceuticals, Inc. Method of Cancer Treatment with 2-(1H-Indole-3-Carbonyl)-Thiazole-4-Carboxylic Acid Methyl Ester
CA2844119A1 (en) 2011-08-26 2013-03-07 Southern Research Institute Hiv replication inhibitors
US9073881B2 (en) 2011-09-23 2015-07-07 Hoffmann-La Roche Inc. Benzoic acid derivatives

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020183524A1 (en) * 2001-02-14 2002-12-05 Deluca Hector F. Preparations and use of an Ah receptor ligand, 2-(1'h-indole-3'-carbonyl)-thiazole-4-carboxylic acid methyl ester
EP1842541A1 (en) * 2006-03-29 2007-10-10 G.I.M.-Gesellschaft Für Innovative Medizin Gmbh Nfg Ohg Plant components and extracts and uses thereof
WO2009067349A2 (en) * 2007-11-20 2009-05-28 The Brigham And Women's Hospital, Inc. Modulation of the immune response
WO2009070645A1 (en) * 2007-11-29 2009-06-04 The Ohio University Research Foundation Indoles, derivatives, and analogs thereof and uses thereof
WO2009117597A1 (en) * 2008-03-21 2009-09-24 The Brigham And Women's Hospital, Inc. Modulation of the immune response

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108239083A (zh) * 2016-12-26 2018-07-03 上海正基医药科技有限公司 芳香烃受体调节剂
WO2018121434A1 (zh) 2016-12-26 2018-07-05 上海正基医药科技有限公司 芳香烃受体调节剂
CN108239083B (zh) * 2016-12-26 2021-08-17 阿里根公司 芳香烃受体调节剂
CN113480530A (zh) * 2016-12-26 2021-10-08 阿里根公司 芳香烃受体调节剂
US11547698B2 (en) 2016-12-26 2023-01-10 Ariagen, Inc. Aryl hydrocarbon receptor modulators
CN113906021A (zh) * 2019-04-15 2022-01-07 阿里根公司 手性吲哚化合物及其用途

Also Published As

Publication number Publication date
US20200323827A1 (en) 2020-10-15
US20170333401A1 (en) 2017-11-23
ES2791684T3 (es) 2020-11-05
JP5598775B2 (ja) 2014-10-01
JP2013509411A (ja) 2013-03-14
US9694000B2 (en) 2017-07-04
EP2496081A4 (en) 2013-05-01
US20160136139A1 (en) 2016-05-19
EP3689347A1 (en) 2020-08-05
AU2010313622B2 (en) 2014-08-14
EP2496081A1 (en) 2012-09-12
NZ702914A (en) 2016-05-27
EP2496081B1 (en) 2020-03-25
CA2776319A1 (en) 2011-05-05
US10195182B2 (en) 2019-02-05
US20130310429A1 (en) 2013-11-21
NZ599896A (en) 2015-09-25
CA2776319C (en) 2018-01-02
AU2010313622A1 (en) 2012-05-31
US9238645B2 (en) 2016-01-19
WO2011053466A1 (en) 2011-05-05
US20120214853A1 (en) 2012-08-23
CN106588908A (zh) 2017-04-26
US20190275011A1 (en) 2019-09-12
US8604067B2 (en) 2013-12-10

Similar Documents

Publication Publication Date Title
CN102573470A (zh) 用于介入治疗和根除癌症的ite
US10993949B2 (en) 17α-monoesters and 17α,21-diesters of cortexolone for use in the treatment of tumors
JP5998137B2 (ja) 前立腺癌を処置するための併用療法
EP3791897A1 (en) Hsp90 inhibitor drug conjugates
US20130338201A1 (en) Method of Cancer Treatment with 2-(1H-Indole-3-Carbonyl)-Thiazole-4-Carboxylic Acid Methyl Ester
CA2767808A1 (en) Compositions and methods for inhibition of cancers
CA2522980A1 (en) Water soluble wortmannin derivatives
US9539237B2 (en) Compositions and methods for drug-sensitization or inhibition of a cancer cell
WO2009107322A1 (ja) がん治療用医薬組成物
ES2991018T3 (es) (N-(2-((2-bencilfenil)amino)-2-oxoetil)-L-naftamida) como agente terapéutico anticanceroso
US10632106B2 (en) Methods of cancer treatment with 2-(1′H-Indole-3′-carbonyl)-thiazole-4-carboxylic acid methyl ester
HK40035247A (en) Ite for cancer intervention and eradication
Zeppa Integrative Therapies in Human Pancreatic Ductal Adenocarcinoma: a preclinical investigation
HK1229695A1 (en) Novel methods for treating cancer

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C53 Correction of patent of invention or patent application
CB02 Change of applicant information

Address after: Wisconsin

Applicant after: Song Jiasheng

Address before: Wisconsin

Applicant before: Song Jiasheng

CB03 Change of inventor or designer information

Inventor after: Song Jiasheng

Inventor before: Song Jiasheng

C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20120711

RJ01 Rejection of invention patent application after publication